Brief: Glenmark Pharma Says Unit Ichnos Glenmark Innovation Received Upfront Payment Of $700 Million From AbbVie
09/09/2025 04:22
Sept 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: GLENMARK PHARMA - ICHNOS GLENMARK INNOVATION RECEIVED UPFRONT PAYMENT OF $700 MILLION FROM ABBVIE GLENMARK PHARMA - PAYMENT FOR EXCLUSIVE GLOBAL LICENSING AGREEMENT FOR ISB 2001 Further company coverage: GLEN.NS ((reuters.briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter